Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
Same as current

Summary

Conditions
Recurrent Ovarian Carcinoma
Design
Observational Model: CohortTime Perspective: Prospective

Participation Requirements

Age
Between 18 years and 99 years
Gender
Only males

Description

Patients at their first platinum-sensitive ROC will be invited to participate in the register. These are all patients with recurrent disease 6 or more months after the last cycle of platinum containing chemotherapy. The Observation Period will begin by signing the Informed Consent Form (ICF) and wil...

Patients at their first platinum-sensitive ROC will be invited to participate in the register. These are all patients with recurrent disease 6 or more months after the last cycle of platinum containing chemotherapy. The Observation Period will begin by signing the Informed Consent Form (ICF) and will continue for up to a total of 24 months (+/- 4 weeks) after the diagnosis of the first relapse or until patient discontinuation for any reason, or patient's death. Data on First Study Visit, Subsequent Recurrence during Observation Period and Last Observation will be collected in the electroinic Case Report Form (eCRF). The register will identify symptoms and factors that led to the diagnosis, chosen therapy and the reason for choosing the therapy. At inclusion, data on general patient information, primary diagnosis, previous therapy, and tumor characteristics are collected. During the course of observation data on systemic and maintenance treatments, radiotherapies, surgeries, and outcome are documented.

Tracking Information

NCT #
NCT04369352
Collaborators
Not Provided
Investigators
Principal Investigator: Lukas Hefler, Prim. Dr. Ordensklinikum Linz